Announcement PDF ASX : EMD Responding To Australia’s Mental Health Crisis Advanced therapies. Compassionate care. 28 August 2025 Company Update Disclaimer This presentation has been prepared by Emyria Limited ACN 625 085 734 (Company or Emyria). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securities in Emyria in any jurisdiction. This presentation contains general information only and does not consider the investment objectives, financial situation and needs of individual investors. Investors should make their own independent assessment of the information in this presentation and obtain their own independent advice from a qualified financial adviser having regard to their personal objectives, financial situation and needs before taking any action. No representation or warranty, express or implied, is made as to the accuracy, completeness, reliability or adequacy of any statements, estimates, opinions or other information, or the reasonableness of any assumption or other statement, contained in this presentation. Nor is any representation or warranty (express or implied) given as to the accuracy, completeness, likelihood of achievement or reasonableness of any forecasts, prospective statements or returns contained in this presentation. Such forecasts, prospective statements or returns are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Emyria. To the maximum extent permitted by law, Emyria and its related bodies corporate, directors, officers, employees, advisers and agents disclaim all liability and responsibility (including without limitation any liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use or reliance on anything contained in, or omitted from, this presentation. An investment in Emyria securities should be considered speculative and is subject to investment and other known and unknown risks, some of which are beyond the control of Emyria. Emyria does not guarantee any rate of return or the absolute or relative investment performance of Emyria securities. The distribution of this presentation including in jurisdictions outside Australia, may be restricted by law. Any person who receives this presentation must seek advice on and observe any such restrictions. This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of Emyria and certain of the plans and objectives of Emyria with respect to these items. These forward-looking statements are not historical facts but rather are based on Emyria's current expectations, estimates and projections about the industry in which Emyria operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Emyria, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Emyria cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Emyria only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Emyria will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority. All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown. The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products’ ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy. 2 Advanced therapies. Compassionate care. Corporate Overview ASX: EMD Trading Information Share Price Last Traded Share Price A$0.050 12-Month low / high A$0.021 / 0.058 Shares Outstanding3 664,160,825 Unlisted Options2 150,390,328 Market Capitalisation 1 ~A$32.0M Last Cash Position 2 ~A$4,685M Shareholding Substantial Shareholder Shareholder % #1 Holder: Greg Hutchinson, Exec. Chairman2 6.42% 39% Top 50 NOTES: 1. As of close of market 27 August 2025 2. As reported in June 2025 Quarterly Report, with an additional $1,115m approved at 19 August 2025 EGM 3. Post Tranche 2 allotment 3 Advanced therapies. Compassionate care. Mental Health Is Australia’s #1, Rising, Chronic Health Problem Inaki Ereno Figure2 : Types of serious illness by age and sex, 2009 to 2021 Bupa CEO 18% 16% Depression / Anxiety 14% 12% 10% 8% Mental health is the new pandemic but the provision of mental health … services is very fragmented, not only in Australia but everywhere. 6% Cancer 4% 2% Inaki Ereno 0% 2009 2013 2017 2021 Bupa’s Global CEO May 17, 2025 - 9.00am 4 Advanced therapies. Compassionate care. Major Funders Are Spending Hundreds of Millions Each Year on Mental Health Private Health Insurers Department of Veterans’ Affairs Other Insurers $2B The Government spends on veteran mental health each year. 2 Life insurers … paid out more than spent by Medibank on mental health hospitalisations in last 10 years, $219M/yr $300M/yr $2.2B in 2024 for retail mental health claims in 2024 4 Almost three in four (veterans) are estimated to have met criteria for a mental disorder at some stage in their lifetime. 3 in 2024 alone. 1 Only 26% of insured adults SOURCES: 1. https://www.heraldsun.com.au/health/mental-health/alarming-research-shows-extent-of-mental-health-crisis-in-australia/news-story/66f6937a316f9dd54673c5a6f692b232 2. https://www.dva.gov.au/sites/default/files/twrp_mhpr.pdf 3. https://www.dva.gov.au/news/latest-stories/report-hospitalisations-suicidality-and-self-harm-released#:~:text=The%20Australian%20Government%20is%20committed,%E2%80%93%20Veterans%20&%20Families%20Counselling%20Service. 4. https://www.abc.net.au/news/2025-07-16/spike-in-mental-health-illness-claims-super-funds-delay-payouts/105531022 5 Advanced therapies. Compassionate care. Australia’s Unique Opportunity An Access Pathway For Psychedelics to Treat our Most Serious and Urgent Mental Health Conditions MDMA-assisted therapy Australia for PTSD is the FIRST jurisdiction in the world to reschedule two promising treatments Psilocybin-assisted therapy for Depression 6 Advanced therapies. Compassionate care. Total Addressable Market | PTSD Adults with difficult to treat PTSD in Australia Early Target Markets ~29,000 current patients Australian Adults With PTSD ~1,500,000 ~7% of all adults Serviceable Addressable Market (SAM) 1 ~585,000 eligible for MDMA-AT ~50% with treatment resistance ~78% of these, medically suitable With Hospital Cover (~5% Adults 2) ~34,000 current patients Veterans (~17% of Veterans w PTSD 34) ~2,000 new cases / yr Workers Compensation (~12% of mental health WC claims 5) ~$33,000 6 / Treatment SOURCES: 1. https://www.abs.gov.au/statistics/health/mental-health/national-study-mental-health-and-wellbeing/latest-release#key-statistics 2. https://www1.racgp.org.au/newsgp/clinical/new-treatment-for-resistant-depression-added-to-pb 3. https://www.dva.gov.au/newsroom/vetaffairs/vetaffairs-vol-40-no3-december-2024/lets-talk-about-post-traumatic-stress-disorder 4. https://www.dva.gov.au/sites/default/files/twrp_mhpr.pdf 5 https://www.safeworkaustralia.gov.au/system/files/documents/1702/work-related-mental-disorders-profile.pdf 6. Average full treatment cost assuming 3 treatment cycles completed 7 Advanced therapies. Compassionate care. Total Addressable Market | Treatment Resistant Depression Adults with difficult to treat depression in Australia Early Target Markets ~20,000 current patients Australian Adults With Major Depression ~1,100,000 ~4% of adults have major depression 1 Serviceable Addressable Market (SAM) ~411,000 eligible for Psilocybin-AT ~33% treatment resistant depression (TRD) with Hospital Cover (~5% Adults 2) ~18,300 current patients Veterans (~11.1% of Veterans w TRD 3) ~1,000 new cases / yr Workers Compensation (~7% of mental health WC claims 4) ~$22,000 5 / Treatment SOURCES: 1. https://www.abs.gov.au/statistics/health/mental-health/national-study-mental-health-and-wellbeing/latest-release#key-statistics 2. https://www1.racgp.org.au/newsgp/clinical/new-treatment-for-resistant-depression-added-to-pb 3. https://www.dva.gov.au/sites/default/files/twrp_mhpr.pdf 4 https://www.safeworkaustralia.gov.au/system/files/documents/1702/work-related-mental-disorders-profile.pdf 5. Average full treatment cost assuming 2 treatment cycles completed 8 Advanced therapies. Compassionate care. Emyria Has Overcome Major Barriers To Psychedelic Delivery And Is Now Building An Operational Moat Skilled Therapists Authorised Prescribers Proven Clinical Model 9 Secure Drug Supply Third Party Funding Fit-for- Purpose Facilities Advanced therapies. Compassionate care. Emyria’s P-AT Treatment Model Medication, ~90 hours of Supervised Intensive Psychotherapy, Follow-Up ACTIVE TREATMENT PROTOCOL DOSING CYCLE 1 DOSING CYCLE 2 Dosing Day 1 (8 hrs) Dosing Day 2 (8 hrs) Follow up Therapy Sessions x 3 Follow up Therapy Sessions x 3 SCREENING AND PREPARATION DOSING CYCLE 3 Dosing Day 3 (8 hrs) PTSD only Follow up Therapy Sessions x 3 Each dosing cycle (medication and therapy) ~$10,000 / patient 10 Advanced therapies. Compassionate care. FOLLOW-UP PERIOD (12 months from last Treatment Cycle) Emyria’s PTSD Program Is Delivering Results Case Study Kate | From “Permanent Disability” To Back at Work MDMA-AT commenced 5 years PCL-5 < 30 Kate’s story: First responder 70 60 • PTSD due to cumulative workplace traumas PCL-5 SCORE 1 50 40 6m 30 • Stuck, terrified and tortured by her unrelenting symptoms and her psychological defenses. 20 10 • Despite all efforts and commitment, treatment and therapy resistant 0 2018 2019 2020 2021 2022 2023 2024 Date SOURCES: 1. The PCL-5 is a self-administered, 20-item self-report tool used to measure PTSD symptoms according to diagnostic DSM-5 criteria (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition). 11 • Myriad of therapies: EMDR, in-vivo, ACT, CBT, mindfulness, somatic exercises, TMS, imagery rescripting, nightmare rescripting. Different psychotropic medications Advanced therapies. Compassionate care. Following MDMA-AT, Kate is back at work after nearly 5 years. Emyria’s PTSD Program Is Delivering Durable Results Durable symptom and quality of life improvement, beyond 6 months from a single treatment Average PCL-5 1 Scores by Visit (up to 6 months follow-up) Typical last treatment Emyria Real-World Data as of August 1st 2025 >60% of patients no longer meet criteria for PTSD diagnosis Patients continue to improve after active treatment has ended. Baseline End of 1st Cycle End of End of 2nd Cycle 3rd Cycle 3 months after end of treatment 6 months after end of treatment SOURCES: 1. The PCL-5 is a self-administered, 20-item self-report tool used to measure PTSD symptoms according to diagnostic DSM-5 criteria (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition). 12 Advanced therapies. Compassionate care. 80% of patients have a clinically significant improvement Emyria’s PTSD Program Is Delivering Results Durable symptom and quality of life improvement, beyond 6 months from a single treatment Baseline Our Empax Model matches Phase 3 trial outcomes out to 6 months. % of patients with PTSD diagnosis after course of treatment 1 0% drop-out MDMA-AT Phase 3 Trials 2 4% drop-out SOURCES: 1. The PCL-5 is a self-administered, 20-item self-report tool used to measure PTSD symptoms according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. Scores of <32 = “loss of diagnosis” 2. S. Mitchell 2023, G. Mitchell 2023 3. See ASX release 28th May 2025 13 Advanced therapies. Compassionate care. Empax PTSD Program Real-World Program 3 Medibank Agreement Emyria is the only provider Medibank has currently partnered with Multi-year agreement1 Fully fund eligible, screened patients1 Uncapped patient numbers1 Initially MDMA-AT for PTSD1 Treatments have commenced in Perth2 Treatment to take place in hospital setting1 SOURCES: 1. See ASX Release 16 June 2025 2. See ASX Release 26 August 2025 14 Advanced therapies. Compassionate care. Other Funders DVA > Workers Compensation > Others Workers Compensation and other funders Case by case funding approval occuring First responders more likely to experience PTSD2 DVA to fund Psychedelic Assisted Therapies for its members1 1.https://www.blackdoginstitute.org.au/news/first-responder-ptsd-rates-rise 2.https://www.theaustralian.com.au/subscribe/news/1/?sourceCode=TAWEB_WRE170_a_GGL&dest=https%3A%2F%2Fwww.theaustralian.com.au%2Fhealth%2Fmental-health%2Fdva-to-fund-psychedelic-medi cine-for-veterans-with-ptsd-depression%2Fnews-story%2F4a56bca1577561bf22fe6368f3d2fb91&memtype=anonymous&mode=premium&v21=GROUPA-Segment-2-NOSCORE&V21spcbehaviour=append 15 Advanced therapies. Compassionate care. Emyria’s PTSD Program | Return-To-Work Progress To Date, 10 Out of 10 Patients With Work-related PTSD Have Returned To Work 6 M Post-treatment 6-8 weeks 0% working 6-months 25% planning return to work 100% back to gainful employment Start of treatment End of treatment 6m post treatment 16 Advanced therapies. Compassionate care. Emyria’s Funded Care Pathways Pipeline Medibank’s PTSD program in WA is the first of many potential funded care pathways Scoping Planning Payer 1 (Melbourne) Payer 1 (Melbourne) Payer 2 (Perth) Payer 2 (Brisbane) Payer 2 (Perth) Payer 1 (Brisbane) Payer 1 (Perth) Payer 1 (Sydney) Payer 3 (WA) Payer 1 (Sydney) Active 1 Payer 2 (Brisbane) Payer 1 (Brisbane) Payer 3 (Perth) PTSD Depression New indications SOURCES: 1. See ASX Release 18 June 2025 17 Payer 1 (Perth) Advanced therapies. Compassionate care. :Further future growth supported by Adding Payers (eg. Workers Comp, DVA, etc) • Adding Sites (WA, Qld, + others in planning) • Expanding indications beyond PTSD and TRD • To Meet Rising Patient Demand, Emyria Is Accelerating a National Roll-out (1) Community Clinic 1 3 1 2 (2) Perth Clinic 2 Current Sites Near term potential sites SOURCES: 1. See ASX release 14th April 2025 2. See ASX release 29 July 2025 18 (3) Avive Clinic (QLD) 3 Advanced therapies. Compassionate care. Emyria’s Growth Strategy Total Funded Dosing Days Available / week Secure Site Partners > Grow Capacity > Optimise Utilisation Additional East Coast sites under consideration Future target Avive site active (Qld) Expansion within WA 1 35 WA 10 4 today Q3 Q4 SOURCES: 1. See ASX Release 26 August 2025 19 Currently active or in preparation Advanced therapies. Compassionate care. Emyria (ASX:EMD) | Upcoming Milestones Target activities Grow capacity nationally Expand funded programs to via new site partners include Depression Treatment Optimise utilisation to Expand funders for our grow revenues programs 20 Advanced therapies. Compassionate care. Why Invest Now? Unique Timing. Proven Model. Overcome High Barriers To Entry. Programs Funded. is tackling some of the most serious health challenges of our generation First Mover Advantages 21 High Barriers Overcome Advanced therapies. Compassionate care. Immediate Growth Potential Emyria Board Significant Clinical Services & Global Innovation Expertise Greg Hutchinson Dr Michael Winlo Dr Karen Smith Dr Mohit Kaushal Prof Sir John Tooke Executive Chairman Executive Director Non-Executive Director Non-Executive Director Non-Executive Director Health Service Leadership: Research & Data Expertise: Biopharma Executive: Health IT Strategist: 5D Clinics Ex-Palantir healthcare lead, Medical Doctor and Stanford MBA 100+ clinical trials and 20+ regulatory approvals; Former Chief Medical Officer and Global Head of R&D at Jazz Pharma Key role in Oak Street Health's $10.6B acquisition by CVS Health; Served in Obama’s Health IT task force; Adjunct Professor at Stanford Former CEO Sonic HealthPlus leading 40+ clinics 22 Advanced therapies. Compassionate care. Clinical Service & Health Payer Expertise: Former President of the Academy of Medical Sciences, influential roles at BUPA and past advisor to Google DeepMind Contact Information Greg Hutchinson ghutchinson@emyria.com Mary-Ann Rennie mrennie@emyria.com Investor / Media Inquiries investors@emyria.com Visit Our Investor Hub